APIRx Pharmaceuticals B.V. is a leading pharmaceutical company dedicated to manufacturing of natural cannabinoid API’s (Active Pharmaceutical Ingredients), which are extracted from cannabis plant material and purified to pharma grade. All manufacturing stages are performed under cGMP conditions. The following cannabinoids are in our product portfolio:
- Tetrahydrocannabinol (THC or Delta-9THC)
- Cannabidiol (CBD)
- Cannabidgerol (CBG)
APIRx also uses its own API’s for the development of new Rx and OTC drugs, nutraceuticals, cosmeceuticals and other products.
APIRx was born out of the growing need for cannabinoid-based solutions for wound healing, dermatological diseases, medication’ related osteonecrosis of the jaws (MRONJ), appetite control and a number of other indications. To date, only synthetically produced cannabinoids have received cGMP certification–but these are quite expensive and artificial. APIRx’s products are cGMP certified, based on 100% natural cannabis plant products–and much more affordable. We believe that the market is headed in the natural cGMP direction from a regulatory compliance and consumer demand perspectives.
In addition to proprietary extraction and purification technologies APIRx implements unique encapsulation technology, which increase bioavailability of cannabinoid APIs and prevents their oxidation and degradation.
The World's Only Provider of cGMP API's Based on Naturally Extracted Cannabinoids
Disruptive Technology in the Rapidly Growing Cannabis Industry
APIRx is part of a large and rapidly growing market opportunity in worldwide cannabis consumption for medicinal usage, which is constantly being re-forecasted, driven by regulatory adoption at state and federal levels (in certain countries). While certain companies have received cGMP certification for certain manufacturing processes, APIRx is the first company to offer APIs and finished good based on an end-to-end cGMP process, starting with cGMP-produced Cannabis plant.
Current products are based on cGMP based synthetic cannabinoids (THC and CBD) but these are extremely expensive and are prone to manufacturing errors, which could be detrimental. The production of synthetic cannabinoids is a costly, multi-step process where the slightest error may lead to devastating consequences. This is not the case with the naturally procured cannabinoids. Currently, there are two regulated (EMA, FDA, etc.) products based on naturally extracted cannabinoids: Sativex (THC and CBD) and Epidiolex (CBD). This signals a shift in the FDA’s position on naturally extracted cannabinoids and willingness to regulate.
Therefore, pharmaceutical and nutraceutical products based on cannabinoids will be regulated and there will be strict guidance as to the acceptability (i.e. they will have to be cGMP compliant). APIRx’s cGMP natural based Cannabis plant products will offer the marketplace decreased cost and safety for consumers.